Marion Peters, MD

Hepatologist

Dr. Marion Peters is a liver specialist, or hepatologist, who treats chronic liver diseases, in particular viral and autoimmune hepatitis, at UCSF Medical Center.

Peters graduated from Melbourne University Medical School, Australia in 1972. She trained in gastroenterology, hepatology and immunology at St. Vincent's Hospital in Melbourne, University of Southern California and the National Institutes of Health. She was chief of Hepatology and medical director of Liver Transplantation at Washington University School of Medicine from 1985 to 1998. She is a professor of medicine at UCSF.

Clinics

Liver Disease and Liver Transplant
350 Parnassus Ave., Suite 300
San Francisco, CA 94143
Phone: (415) 353-2318
Fax: (415) 353-2407

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Conditions & Treatments

Academic Title

Professor

More about Marion Peters

Additional Languages

Spanish

Education

Royal Melbourne Hospital, Australia 1972

Residencies

St. Vincent's Hospital, Melbourne, Internal Medicine 1976

Fellowships

St. Vincent's Hospital, Melbourne, Gastroenterology 1978
University of S. California, Internal Medicine (Liver) 1980

Selected Research and Publications

  1. Reid M, Ma Y, Scherzer R, Price JC, French AL, Huhn GD, Plankey MW, Peters M, Grunfeld C, Tien PC. Contribution of Liver Fibrosis and Microbial Translocation to Immune Activation in Persons Infected With HIV and/or Hepatitis C Virus. J Infect Dis. 2018 Mar 28; 217(8):1289-1297.
  2. Willis SJ, Cole SR, Westreich D, Edmonds A, Hurt CB, Albrecht S, Anastos K, Augenbraun M, Fischl M, French AL, Kalapila AG, Karim R, Peters MG, Plankey M, Seaberg EC, Tien PC, Adimora AA. Chronic hepatitis C virus infection and subsequent HIV viral load among women with HIV initiating antiretroviral therapy. AIDS. 2018 Mar 13; 32(5):653-661.
  3. French AL, Martin JW, Evans CT, Peters M, Kessaye SG, Nowicki M, Kuniholm M, Golub E, Augenbraun M, Desai SN. Macrophage Activation and the Tumor Necrosis Factor Cascade in Hepatitis C Disease Progression Among HIV-Infected Women Participating in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2017 Dec 01; 76(4):438-444.
  4. Kelly EM, Dodge JL, Bacchetti P, Sarkar M, French AL, Tien PC, Glesby MJ, Golub ET, Augenbraun M, Plankey M, Peters MG. Moderate Alcohol Use Is Not Associated With Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women: A Prospective Cohort Study. Clin Infect Dis. 2017 Nov 29; 65(12):2050-2056.
  5. Sarkar M, Dodge JL, Greenblatt RM, Kuniholm MH, DeHovitz J, Plankey M, Kovacs A, French AL, Seaberg EC, Ofotokun I, Fischl M, Overton E, Kelly E, Bacchetti P, Peters MG. Reproductive Aging and Hepatic Fibrosis Progression in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Women. Clin Infect Dis. 2017 Oct 30; 65(10):1695-1702.
  6. Keating SM, Dodge JL, Norris PJ, Heitman J, Gange SJ, French AL, Glesby MJ, Edlin BR, Latham PS, Villacres MC, Greenblatt RM, Peters MG. The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study. PLoS One. 2017; 12(9):e0181004.
  7. Peters MG. Management of Autoimmune Hepatitis in Pregnant Women. Gastroenterol Hepatol (N Y). 2017 Aug; 13(8):504-506.
  8. Peters MG, Locarnini S. New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection. Gastroenterol Hepatol (N Y). 2017 Jun; 13(6):348-356.
  9. Block TM, Locarnini S, McMahon BJ, Rehermann B, Peters MG. Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics. Clin Infect Dis. 2017 05 01; 64(9):1283-1288.
  10. Naggie S, Marks KM, Hughes M, Fierer DS, Macbrayne C, Kim A, Hollabaugh K, Roa J, Symonds B, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Chung R. Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C. Clin Infect Dis. 2017 04 15; 64(8):1035-1042.
  11. Vergara C, Thio C, Latanich R, Cox AL, Kirk GD, Mehta SH, Busch M, Murphy EL, Villacres MC, Peters MG, French AL, Golub E, Eron J, Lahiri CD, Shrestha S, Gustafson D, Young M, Anastos K, Aouizerat B, Kim AY, Lauer G, Thomas DL, Duggal P. Genetic basis for variation in plasma IL-18 levels in persons with chronic hepatitis C virus and human immunodeficiency virus-1 infections. Genes Immun. 2017 03; 18(2):82-87.
  12. Geha R, Peters M, Gill RM, Dhaliwal G. Histology Rings True. N Engl J Med. 2017 03 02; 376(9):869-874.
  13. Price JC, Ma Y, Scherzer R, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection. Hepatology. 2017 03; 65(3):853-863.
  14. Kelly EM, Feldstein VA, Etheridge D, Hudock R, Peters MG. Sonography Predicts Liver Steatosis in Patients With Chronic Hepatitis B. J Ultrasound Med. 2017 May; 36(5):925-932.
  15. Kardashian A, Ma Y, Scherzer R, Price JC, Sarkar M, Korn N, Tillinghast K, Peters MG, Noworolski SM, Tien PC. Sex differences in the association of HIV infection with hepatic steatosis. AIDS. 2017 Jan 28; 31(3):365-373.
  16. Balitzer D, Shafizadeh N, Peters MG, Ferrell LD, Alshak N, Kakar S. Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria. Mod Pathol. 2017 May; 30(5):773-783.
  17. Liu J, Goicochea P, Block T, Brosgart CL, Donaldson EF, Lenz O, Gee Lim S, Marins EG, Mishra P, Peters MG, Miller V. Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders consultation. J Virus Erad. 2017 Jan 01; 3(1):1-6.
  18. Mehta NJ, Celik AD, Peters MG. Screening for hepatocellular carcinoma: What is missing? Hepatol Commun. 2017 Feb; 1(1):18-22.
  19. Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Lo Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clin Infect Dis. 2016 Nov 01; 63(9):1160-1167.
  20. Desai SN, Dodge JL, Landay AL, Glesby MJ, Latham PS, Villacres MC, French AL, Gange SJ, Greenblatt RM, Peters MG. Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study. Medicine (Baltimore). 2016 Aug; 95(33):e4483.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.